Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00064610 · ClinicalTrials.gov registry record · Phase 1
Phase I/II Dose Escalation Study of VELCADE® and Docetaxel in Patients With Advanced Androgen-Independent Prostate Cancer
A Phase 1 study, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 102
- Enrollment target
NCT00064610 is a Phase 1 study that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 102 participants.
The verdict
NCT00064610, a Phase 1 study, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 102 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate how safe PS-341(VELCADE) is when given with Docetaxel (Taxotere) to patients with androgen-independent prostate cancer, and also to see what effects (good and bad) it has on you and on your cancer.
Interventions
- DRUG VELCADE TM (bortezomib) for Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2002-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00064610
The ClinicalTrials.gov registry entry for NCT00064610 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VELCADE TM (bortezomib) for Injection is the first listed.
NCT00064610 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00064610 about?
NCT00064610 is a clinical study titled "Phase I/II Dose Escalation Study of VELCADE® and Docetaxel in Patients With Advanced Androgen-Independent Prostate Cancer". The purpose of this study is to evaluate how safe PS-341(VELCADE) is when given with Docetaxel (Taxotere) to patients with androgen-independent prostate cancer, and also to see what effects (good and bad) it has on you and on your cancer.
What is the current status of trial NCT00064610?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 102 participants. The study started on 2002-12.
What interventions are being tested in trial NCT00064610?
The interventions under investigation include: VELCADE TM (bortezomib) for Injection (DRUG).
Who is sponsoring clinical trial NCT00064610?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.